argenex SE (NASDAQ:ARGX) Shares Sold by Gilbert & Cook Inc.

Gilbert & Cook Inc. lessened its position in shares of argenex SE (NASDAQ:ARGX - Free Report) by 25.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,314 shares of the company's stock after selling 443 shares during the quarter. Gilbert & Cook Inc.'s holdings in argenex were worth $778,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its position in shares of argenex by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Capital World Investors raised its stake in argenex by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after buying an additional 86,687 shares during the last quarter. RTW Investments LP boosted its holdings in argenex by 2.9% in the fourth quarter. RTW Investments LP now owns 673,497 shares of the company's stock worth $414,201,000 after acquiring an additional 19,067 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of argenex by 6.8% during the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after acquiring an additional 40,330 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in shares of argenex by 26.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 206,202 shares of the company's stock valued at $126,814,000 after acquiring an additional 43,239 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

ARGX stock traded up $0.25 during mid-day trading on Friday, reaching $591.99. 493,117 shares of the company's stock were exchanged, compared to its average volume of 430,326. The company has a market cap of $36.23 billion, a price-to-earnings ratio of 36.52, a price-to-earnings-growth ratio of 1.03 and a beta of 0.37. The stock's 50 day moving average is $566.05 and its 200 day moving average is $598.66. argenex SE has a 12-month low of $473.67 and a 12-month high of $678.21.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenex had a return on equity of 16.15% and a net margin of 40.20%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. On average, research analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on ARGX shares. HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenex in a research note on Tuesday, July 1st. JMP Securities set a $699.00 price objective on shares of argenex in a research note on Wednesday, May 14th. Citigroup reissued a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Guggenheim cut their target price on argenex from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Robert W. Baird raised argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research report on Tuesday, May 13th. Nineteen investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $728.06.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.